Biophytis (OTC: BPTSY) suspended share trading on June 15, 2026, following a delayed 2025 annual report, prompting an SEC Form 6-K filing.

Key Highlights

  • Biophytis (OTC: BPTSY) temporarily suspended trading of its shares on June 15, 2026, pending resolution of a delayed 2025 annual report.
  • The company filed a Form 6-K with the SEC on June 16, 2026, under Commission File Number 001-38974.
  • The filing referenced an attached press release as Exhibit 99.1, confirming the trading halt.
  • No specific timeline was provided for the resumption of trading or the release of the overdue financial report.
  • The suspension follows regulatory requirements under the Securities Exchange Act of 1934.

Biophytis (OTC: BPTSY) has halted trading of its shares after failing to file its 2025 annual report on schedule.

The suspension, effective June 15, 2026, was disclosed in a regulatory filing submitted to the U.S.

Securities and Exchange Commission the following day.

The document was signed by Stanislas Veillet, Biophytis’ Chairman and Chief Executive Officer, at the company’s Paris headquarters located at 4 place Jussieu, 75005.

The filing referenced the Securities Exchange Act of 1934, which governs reporting obligations for foreign private issuers.

The delay in the 2025 annual report has raised questions among investors about the company’s financial health and compliance with regulatory deadlines.

Biophytis, a clinical-stage biotech firm focused on age-related diseases, has not provided a revised timeline for the report’s release or the resumption of trading.

Such delays can trigger automatic trading halts under SEC rules, particularly for companies listed on over-the-counter markets.

Market reaction to the news has been muted but cautious.

Biophytis’ shares, which trade on the OTC market, had already faced volatility in recent months amid clinical trial updates and funding challenges.

The trading halt adds another layer of uncertainty for shareholders, who may now face an extended period without price discovery.

Analysts note that annual report delays are not uncommon in the biotech sector, where companies often grapple with complex accounting for research and development expenses.

However, prolonged delays can erode investor confidence and may lead to additional regulatory scrutiny.

The SEC’s Form 6-K filing, while procedural, serves as a formal notice to the market of the company’s non-compliance.

Biophytis’ next steps will be closely watched.

The company must file its 2025 annual report to lift the trading suspension, though no deadline has been specified in the filing.

Investors are likely to seek clarity on the reasons behind the delay, particularly given the company’s ongoing clinical programs and cash runway concerns.

The broader biotech sector has seen increased regulatory oversight in recent years, with the SEC emphasizing transparency in financial disclosures.

Companies that fail to meet filing deadlines risk delisting or other enforcement actions, though Biophytis’ status as a foreign private issuer may influence the SEC’s response.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.